FDA clears hearing-loss gene therapy: first treatment aimed at restoring hearing

The Food and Drug Administration has approved a first-of-its-kind gene therapy for a hereditary form of deafness, offering the first therapy that directly targets the underlying genetic cause of severe to profound OTOF-related hearing loss. The decision — granted under a pilot fast‑track program — could change care options for both children and adults and sets a precedent for reviewing complex gene therapies more quickly.

The product, marketed as Otarmeni (lunsotogene parvec-cwha), uses a novel two‑vector adeno‑associated virus approach to deliver a working copy of the OTOF gene into the inner ear. Regulators say it is intended for patients who retain outer hair‑cell function and who have not received a cochlear implant in the ear to be treated.

Clinical data published in The New England Journal of Medicine in 2025 reported measurable hearing improvement after treatment. In that trial, several participants regained natural acoustic hearing and a subset achieved normalized auditory sensitivity — findings researchers described as proof that replacing the missing gene product, otoferlin, can restore the ear’s ability to send signals to the brain.

How the treatment is given and what to expect

Otarmeni is a one‑time, surgical procedure performed bilaterally. Physicians deliver the therapeutic material directly into the cochlea using a fine needle and microcatheter. Because the therapy is invasive, common adverse events observed in trials included middle ear infections, nausea, dizziness and procedural pain.

Regulators emphasized that the therapy is not suitable for everyone with genetic hearing loss; suitable candidates must meet specific physiologic criteria assessed by audiologic and imaging studies. The FDA plans a public meeting on June 4 to clarify distribution plans, eligibility rules and other implementation details.

• Treatment name: Otarmeni (lunsotogene parvec-cwha)
• Technology: Dual AAV vector gene replacement delivered to the cochlea
• Target: Biallelic pathogenic variants in the OTOF gene causing severe to profound hearing loss
• Administration: Single surgical dosing to both ears via cochlear infusion
• Key trial outcome: Improved auditory function in treated patients; some achieved near‑normal hearing sensitivity
• Common side effects: Middle ear infection, nausea, dizziness, procedural pain
• Next steps: FDA public meeting June 4 to discuss rollout and eligibility

Regulatory context and implications

The approval was processed through the FDA’s National Priority Voucher pilot program, a pathway designed to accelerate review of treatments for rare conditions. According to agency materials, this marks the sixth approval managed under that initiative and the first gene therapy cleared through the pilot — a milestone that may influence how future complex biologics are evaluated and scheduled.

For clinicians and families, the decision introduces a new option that addresses the genetic defect rather than only managing symptoms with devices such as cochlear implants. For health systems, it raises questions about patient selection, surgical capacity, long‑term follow‑up and coverage decisions.

Officials say more data and real‑world monitoring will be critical to understanding durability, broader safety, and outcomes across age groups. The June public meeting will be the first opportunity for stakeholders — clinicians, researchers, patients and payers — to hear details about distribution, eligibility criteria and post‑approval surveillance plans.